Results 151 to 160 of about 48,562 (198)

Janus kinase inhibitors for alopecia areata: a review of clinical data. [PDF]

Front Immunol
Sun Y, Li Q, Zhang Y, Liu Y.
europepmc   +1 more source

Machine learning-based prediction of response to Janus kinase inhibitors in patients with rheumatoid arthritis using clinical data. [PDF]

Front Immunol
Lee YJ, Choi G, Yeo J, Baek J, Choi H, Kim M, Kim YG, Kim BY, Koo J.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Janus kinase inhibitors: efficacy and safety

Current Opinion in Rheumatology, 2023
Purpose of review Janus kinase inhibitors (JAKi) have been available for the treatment of rheumatoid arthritis (RA) since 2012 and are indicated for patients with active disease despite csDMARD therapy. Efficacy and safety, as demonstrated in the clinical trials, was similar to biologics. A recent post marketing trial suggested
Stanley, Cohen, Virginia, Reddy
openaire   +2 more sources

Janus kinase inhibitors for alopecia areata

Journal of the American Academy of Dermatology, 2023
Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and ...
Brett A, King, Brittany G, Craiglow
openaire   +2 more sources

Investigational Janus kinase inhibitors

Expert Opinion on Investigational Drugs, 2013
Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire   +2 more sources

Efficacy of Janus kinase inhibitors in rheumatoid arthritis

Inflammation Research, 2023
Janus kinase inhibitors (JAKis) is a new therapeutic class in autoimmune and inflammatory diseases. Four molecules are approved in rheumatoid arthritis (RA) in Europe. Recently, questions have raised about adverse events. In this context, a synthesis of the efficacy data of JAKis in RA is of use.We performed a literature review based on published ...
Camille, Langbour, Jessica, Rene, Philippe, Goupille, Guillermo, Carvajal Alegria   +3 more
openaire   +2 more sources

Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)

Bioorganic & Medicinal Chemistry Letters, 2009
A series of phenylaminopyrimidines has been identified as inhibitors of Janus kinases (JAKs). Development of this initial series led to the potent JAK2/JAK1 inhibitor CYT387 (N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide). Details of synthesis and SAR studies of these compounds are reported.
Burns, Christopher J., Bourke, David G., Andrau, Laura, Bu, Xianyong, Charman, Susan A., Donohue, Andrew C., Fantino, Emmanuelle, Farrugia, Michelle, Feutrill, John T., Joffe, Max, Kling, Marcel R., Kurek, Margarita, Nero, Tracy L., Nguyen, Thao, Palmer, James T., Phillips, Ian, Shackleford, David M, Sikanyika, Harrison, Styles, Michelle, Su, Stephen, Treutlein, Herbert, Zeng, Jun, Wilks, Andrew F.   +22 more
openaire   +5 more sources

Oral Janus kinase inhibitors for atopic dermatitis

Annals of Allergy, Asthma & Immunology, 2023
Atopic dermatitis (AD) is one of the most common inflammatory skin conditions. The pathogenesis of AD involves skin barrier disruption and immune activation of T-helper (TH)2 and TH22 and varying degrees of TH1 and TH17 activation in various patient subtypes.
Daniela, Mikhaylov, Benjamin, Ungar, Yael, Renert-Yuval, Emma, Guttman-Yassky   +3 more
openaire   +2 more sources

Dehydrocrenatidine Is a Novel Janus Kinase Inhibitor

Molecular Pharmacology, 2015
Janus kinase (JAK) 2 plays a pivotal role in the tumorigenesis of signal transducers and activators of transcription (STAT) 3 constitutively activated solid tumors. JAK2 mutations are involved in the pathogenesis of various types of hematopoietic disorders, such as myeloproliferative disorders, polycythemia vera, essential thrombocythemia, and primary ...
Jing, Zhang, Ning, Zhu, Yuping, Du, Qifeng, Bai, Xing, Chen, Jing, Nan, Xiaodong, Qin, Xinxin, Zhang, Jianwen, Hou, Qin, Wang, Jinbo, Yang   +10 more
openaire   +2 more sources

Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo

Mini-Reviews in Medicinal Chemistry, 2021
Abstract: The small-molecular inhibitors targeted JAks (JAK inhibitors), could modulate the cytokines-mediated signaling via JAK-STAT pathway, which plays a important role in immune regulation and cell proliferation. The JAK inhibitors are previously designed and synthesized to treat diseases involved with hematologic and immune system.
Chao, Niu, Hunjun, Xie, Haji Akber, Aisa
openaire   +2 more sources